IPO
8 articles
IPO lock-up periods explained: who is bound and what happens at expiry
What an IPO lock-up period is, who must hold their shares, how long lock-ups usually last, and why the expiration date can matter for a newly public stock.
Reading a 424B4 final prospectus: a section-by-section guide
What a 424B4 final prospectus is, when it is filed, and how to read its cover page, underwriting, dilution and use of proceeds sections, step by step.
Electra Therapeutics IPO Pricing: $350 Million at $15 a Share
Electra Therapeutics priced 23.3 million shares at $15 in its September 2026 Nasdaq IPO. Our review of the 424B4 prospectus, pipeline, losses and cash.
How IPO pricing works: from price range to final prospectus
How IPO pricing works: underwriters, the order book, the price range and the final 424B4 prospectus, explained in plain English for general readers today.
Jersey Mike's IPO Pricing: $23 a Share and a $1 Billion Offering
Jersey Mike's Subs priced 43.5 million shares at $23 in its July 2026 NYSE IPO, a $1 billion deal. Our 424B4 review covers proceeds, debt and control.
Kardigan IPO Pricing: $400 Million Raised at $16 a Share
Cardiovascular biotech Kardigan priced 25 million shares at $16 in its June 2026 Nasdaq IPO. Our 424B4 review covers proceeds, pipeline, losses and cash.
Lincoln International IPO Pricing: $20 a Share in NYSE Debut
Lincoln International priced 21 million Class A shares at $20 in its May 2026 NYSE IPO. Our 424B4 review covers proceeds, debt paydown and partner control.
Cerebras IPO Pricing Review: $185 a Share in the 424B4 Prospectus
Cerebras Systems priced 30 million Class A shares at $185 in its May 2026 IPO, raising $5.55 billion on Nasdaq. Our review of the final 424B4 prospectus.